目的: 观察何首乌、润燥止痒胶囊和百乐眠胶囊引起的中草药相关肝损伤(HILI)在接受中医药治疗人群中的可能发生率,探索其危险因素。方法: 以2020年1月至2022年6月在上海中医药大学附属曙光医院门诊接受中医药治疗时曾运用何首乌、润燥止痒胶囊、百乐眠胶囊的患者为研究对象,分析HILI发生的可能性。结果: 运用何首乌导致HILI的可能发生率为2.64‰,运用润燥止痒胶囊导致HILI的可能发生率为2.40‰,运用百乐眠胶囊导致HILI的可能发生率为2.06‰。甲状腺疾病是影响服用百乐眠胶囊患者HILI发生的危险因素(P<0.001)。结论: 何首乌及其中成药制剂导致的中草药相关肝损伤发生率较低,应当正确评价中草药相关肝损伤,安全合理应用中药。
Abstract
Objective: Observing the possible incidence of herb-induced liver injury (HILI) caused by Polygoni Multiflori Radix Praeparata, Run-Zao-Zhi-Yang capsules and Bai-Le-Mian capsules in the population receiving traditional Chinese medicine treatment and exploring their risk factors. Methods: A retrospective study was conducted to analyze the possibility of incidence of HILI in patients who used Polygoni Multiflori Radix Praeparata, Run-Zao-Zhi-Yang capsules and Bai-Le-Mian capsules while receiving traditional Chinese medicine treatment in the outpatient clinic of Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine from January 2020 to June 2022. Results: In the outpatient clinic of Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine between January one, 2020, and June 30, 2022, the possibility of incidence of HILI caused by Polygoni Multiflori Radix Praeparata was 2.64‰. The possibility of incidence of HILI caused by Run-Zao-Zhi-Yang Capsules was 2.40‰. The possibility of incidence of HILI caused by Bai-Le-Mian Capsules was 2.06‰. For patients taking Bai-Le-Mian Capsules, having thyroid disease was a risk factor for the occurrence of HILI(P<0.001). Conclusion: The incidence of HILI caused by Polygoni Multiflori Radix Praeparata and its proprietary Chinese patent medicine is low, and HILI should be properly evaluated for the safe and rational application of traditional Chinese medicine.
关键词
中草药相关性肝损伤 /
何首乌 /
中成药
{{custom_keyword}} /
Key words
herb-induced liver injury /
Polygoni Multiflori Radix Praeparata /
Chinese patent medicine
{{custom_keyword}} /
中图分类号:
R575
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 肖小河,李秀惠,朱云,等.中草药相关肝损伤临床诊疗指南[J].临床肝胆病杂志,2016,32(5):835-843.
[2] Wang JB ,Song HB , Ge FL, et al.Landscape of DILI-related adverse drug reaction in China Mainland[J].Acta Pharmaceutica Sinica B,2022,12(12):4424-4431.
[3] 中华中医药学会中成药分会. 何首乌安全用药指南[J].临床肝胆病杂志,2019,35(12):2687-2693.
[4] 用药助手.润燥止痒胶囊.[EB/OL].[2023-02-28].
https://newdrugs.dxy.cn/h5/drugs_description/SZyUZtshO-mepepmltjOA463gfpg==.
[5] 陈莉莉,蔡之幸,陈越.润燥止痒胶囊致肝损伤1例[J].肝脏, 2021,26(12):1423.
[6] 刘园园.润燥止痒胶囊致肝损伤1例[J].肝脏,2020,25(5):556-557.
[7] 田璐璐,周陶然,吴涓,等.润燥止痒胶囊致药物性肝损1例[J].上海医药,2017,38(17):35-37.
[8] 用药助手.百乐眠胶囊[EB/OL].[2023-02-28].
https://newdrugs.dxy.cn/h5/drugs_description/vAoYEZUX-c6o9C6Tz0PM9Mg==.
[9] Categorization of the likelihood of drug induced liver injury. [EB/OL].[2023-02-28]. https://www.ncbi.nlm.nih.gov/books/NBK548392/.
[10] 宋海波,韩玲.中药肝损伤的流行特点、风险因素及评价[J].中国药理学与毒理学杂志, 2016,30(4):291-305.
[11] 涂灿,蒋冰倩,赵艳玲,等.何首乌炮制前后对大鼠肝脏的损伤比较及敏感指标筛选[J].中国中药杂志, 2015,40 (4): 654-660.
[12] 林艳,肖榕,李春等.生/制/发酵何首乌化学成分、药理作用及肝毒性研究进展[J].中药新药与临床药理,2018,29(5):661-672.
[13] 王伽伯,李春雨,朱云,等.基于整合证据链的中草药肝毒性客观辨识与合理用药:以何首乌为例[J].科学通报,2016,61(9):971-980.
[14] 李邻峰,李元文.中成药治疗湿疹临床应用指南(2020年)[J].中国中西医结合杂志, 2021,41(2):133-142.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
*上海市2020年度“科技创新行动计划”医学创新研究专项项目(No.20Z21900100)
{{custom_fund}}